Skip to main content

Illinois IGB

drug discovery

Erik Nelson - A milestone in my career

February 20, 2023

Several days following the Federal Drug Administration’s approval of a new cancer drug, Erik Nelson (ACPP) was still processing the news.

“It hasn’t sunk in yet that this is actually happening,” he said from his breast cancer research lab in Burrill Hall. “This is why I get up every morning: to hopefully impact a patient's life.”


February 20, 2023


Related Articles

AI, molecule machine join forces to generalize automated chemistry

October 31, 2022

Artificial intelligence, “building-block” chemistry and a molecule-making machine teamed up to find the best general reaction conditions for synthesizing chemicals important to biomedical and materials research – a finding that could speed innovation and drug discovery as well as make complex chemistry automated and accessible.


October 31, 2022


Related Articles

Atomic structure of antifungal drug confirms unusual mechanism

December 13, 2021

Advanced molecular imaging technology has now mapped the structure of a drug widely used to treat fungal infections but whose workings have mystified researchers and physicians for nearly 70 years.

In a new study, researchers at the University of Illinois Urbana-Champaign, the University of Wisconsin, Madison and the National Institutes of Health described in atomistic detail the structure of the drug amphotericin B, a powerful but toxic antifungal agent.


December 13, 2021


Related Articles

New approach drives bacteria to produce potential antibiotic, antiparasitic compounds

June 26, 2020

Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbor other untapped chemical riches. The scientists report their findings in the journal eLife.


June 26, 2020


Related Articles

Study yields million-plus new compounds, pharmaceutical potential

March 12, 2018

Researchers say they can now produce a vast library of unique cyclic compounds, some with the capacity to interrupt specific protein-protein interactions that play a role in disease. The new compounds have cyclic structures that give them stability and enhance their ability to bind to their targets.  

The study, reported in the journal Nature Chemical Biology, also revealed that one of the newly generated compounds interferes with the binding of an HIV protein to a human protein, an interaction vital to the virus’s life cycle.


March 12, 2018


Related Articles

Subscribe to drug discovery